{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:58:42Z","timestamp":1791536322356,"version":"4.3.4"},"reference-count":78,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Normocalcemic primary hyperparathyroidism (NPHPT), a phenotype of primary hyperparathyroidism, is characterized by elevated parathyroid hormone levels in the setting of persistently normal serum calcium. Diagnosis of NPHPT can be challenging and requires that secondary causes of hyperparathyroidism be excluded. The natural history of NPHPT remains inconclusive. Although biochemically less severe, the skeletal and renal complications of NPHPT vary across studies, primarily due to underlying selection bias. Due to limited data, there is currently no consensus regarding medical and surgical treatment. Recent studies on parathyroidectomy have indicated that normocalcemic patients present more often with negative preoperative localization studies and multiglandular disease, which complicates successful surgical management. In addition, postoperative improvements in bone mineral density and nephrolithiasis vary, raising questions about the optimal treatment approach. Further studies are needed to provide better evidence-based guidance for normocalcemic patients.<\/jats:p>","DOI":"10.1210\/clinem\/dgae659","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T08:41:23Z","timestamp":1727253683000},"page":"e868-e877","source":"Crossref","is-referenced-by-count":22,"title":["Approach to the Patient: Normocalcemic Primary Hyperparathyroidism"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5448-3626","authenticated-orcid":false,"given":"Yi","family":"Liu","sequence":"first","affiliation":[{"name":"Division of Endocrine, Department of Medicine, New York Presbyterian Hospital, Weill Cornell Medical College , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naina","family":"Sinha Gregory","sequence":"additional","affiliation":[{"name":"Division of Endocrine, Department of Medicine, New York Presbyterian Hospital, Weill Cornell Medical College , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Andreopoulou","sequence":"additional","affiliation":[{"name":"Division of Endocrine, Department of Medicine, New York Presbyterian Hospital, Weill Cornell Medical College , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Kashyap","sequence":"additional","affiliation":[{"name":"Division of Endocrine, Department of Medicine, New York Presbyterian Hospital, Weill Cornell Medical College , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3042-5336","authenticated-orcid":false,"given":"Natalie","family":"Cusano","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, Lenox Hill Hospital, Zucker School of Medicine at Hofstra\/Northwell , New York, NY 10022 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,9,25]]},"reference":[{"issue":"2","key":"2025021815501462200_dgae659-B1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrendo.2017.104","article-title":"Primary hyperparathyroidism","volume":"14","author":"Walker","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"2025021815501462200_dgae659-B2","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1210\/jc.2014-1415","article-title":"Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop","volume":"99","author":"Silverberg","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025021815501462200_dgae659-B3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.amjmed.2014.09.030","article-title":"Hypercalcemic crisis: a clinical review","volume":"128","author":"Ahmad","year":"2015","journal-title":"Am J Med"},{"issue":"11","key":"2025021815501462200_dgae659-B4","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/jbmr.4677","article-title":"Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the fifth international workshop","volume":"37","author":"Bilezikian","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2025021815501462200_dgae659-B5","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1210\/jc.2014-1414","article-title":"Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop","volume":"99","author":"Eastell","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2025021815501462200_dgae659-B6","doi-asserted-by":"crossref","first-page":"5496710","DOI":"10.1155\/2019\/5496710","article-title":"Parathyroid hormone measurement in chronic kidney disease: from basics to clinical implications","volume":"2019","author":"Kritmetapak","year":"2019","journal-title":"Int J Nephrol"},{"issue":"10","key":"2025021815501462200_dgae659-B7","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1210\/jc.2014-1413","article-title":"Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop","volume":"99","author":"Bilezikian","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025021815501462200_dgae659-B8","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.mcna.2021.05.017","article-title":"Evaluation and management of elevated parathyroid hormone levels in normocalcemic patients","volume":"105","author":"Cusano","year":"2021","journal-title":"Med Clin North Am"},{"issue":"10-11","key":"2025021815501462200_dgae659-B9","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.clinbiochem.2011.04.002","article-title":"Biochemical diagnosis of primary hyperparathyroidism: analysis of the sensitivity of total and ionized calcium in combination with PTH","volume":"44","author":"Nordenstrom","year":"2011","journal-title":"Clin Biochem"},{"issue":"9","key":"2025021815501462200_dgae659-B10","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1210\/jc.2012-1429","article-title":"The importance of measuring ionized calcium in characterizing calcium status and diagnosing primary hyperparathyroidism","volume":"97","author":"Ong","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025021815501462200_dgae659-B11","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.amjsurg.2019.10.032","article-title":"Comparative prospective study on the presentation of normocalcemic primary hyperparathyroidism. Is it more aggressive than the hypercalcemic form?","volume":"219","author":"Gomez-Ramirez","year":"2020","journal-title":"Am J Surg"},{"issue":"1","key":"2025021815501462200_dgae659-B12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s00268-016-3716-6","article-title":"Use of calcium and parathyroid hormone nomogram to distinguish between atypical primary hyperparathyroidism and normal patients","volume":"41","author":"Lavryk","year":"2017","journal-title":"World J Surg"},{"key":"2025021815501462200_dgae659-B13","doi-asserted-by":"crossref","first-page":"1268704","DOI":"10.3389\/fendo.2023.1268704","article-title":"Application of calcium-to-phosphorus (Ca\/P) ratio in the diagnosis of pseudohypoparathyroidism: another piece in the puzzle of diagnosis of Ca-P metabolism disorders","volume":"14","author":"De Vincentis","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2025021815501462200_dgae659-B14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eprac.2023.12.004","article-title":"The Ca *Cl\/P ratio: a novel and more appropriate screening tool for normocalcaemic or overt primary hyperparathyroidism","volume":"30","author":"Yu","year":"2024","journal-title":"Endocr Pract"},{"issue":"1","key":"2025021815501462200_dgae659-B15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/cen.14326","article-title":"Reference interval for albumin-adjusted calcium based on a large UK population","volume":"94","author":"Schini","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2025021815501462200_dgae659-B16","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1309\/AJCPU2SKW1TFKSWY","article-title":"Analytical variability among methods for the measurement of 25-hydroxyvitamin D: still adding to the noise","volume":"140","author":"Holmes","year":"2013","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"2025021815501462200_dgae659-B17","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1210\/jc.2011-0385","article-title":"Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline","volume":"96","author":"Holick","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"2025021815501462200_dgae659-B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American association of clinical endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"key":"2025021815501462200_dgae659-B19","doi-asserted-by":"crossref","first-page":"1177829","DOI":"10.3389\/fphys.2023.1177829","article-title":"Pathophysiology of bone disease in chronic kidney disease: from basics to renal osteodystrophy and osteoporosis","volume":"14","author":"Aguilar","year":"2023","journal-title":"Front Physiol"},{"issue":"2","key":"2025021815501462200_dgae659-B20","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","article-title":"Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling","volume":"99","author":"Chesnut","year":"1995","journal-title":"Am J Med"},{"issue":"8","key":"2025021815501462200_dgae659-B21","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"2025021815501462200_dgae659-B22","first-page":"2844","article-title":"Alterations in parathyroid dynamics in lithium-treated subjects","volume":"82","author":"Haden","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025021815501462200_dgae659-B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2023.0228","article-title":"Thiazide diuretics and primary hyperparathyroidism","volume":"84","author":"Mifsud","year":"2023","journal-title":"Br J Hosp Med (Lond)"},{"issue":"2","key":"2025021815501462200_dgae659-B24","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1530\/EJE-21-1044","article-title":"European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE educational program of parathyroid disorders","volume":"186","author":"Bollerslev","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2025021815501462200_dgae659-B25","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1046\/j.1365-2362.2001.00883.x","article-title":"Loop diuretics alter the diurnal rhythm of endogenous parathyroid hormone secretion. A randomized-controlled study on the effects of loop- and thiazide-diuretics on the diurnal rhythms of calcitropic hormones and biochemical bone markers in postmenopausal women","volume":"31","author":"Rejnmark","year":"2001","journal-title":"Eur J Clin Invest"},{"issue":"5","key":"2025021815501462200_dgae659-B26","doi-asserted-by":"crossref","first-page":"666","DOI":"10.20945\/2359-3997000000556","article-title":"Normocalcemic primary hyperparathyroidism","volume":"66","author":"Cusano","year":"2022","journal-title":"Arch Endocrinol Metab"},{"issue":"1","key":"2025021815501462200_dgae659-B27","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1172\/JCI107156","article-title":"Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria","volume":"52","author":"Coe","year":"1973","journal-title":"J Clin Invest"},{"issue":"8","key":"2025021815501462200_dgae659-B28","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1210\/jc.2006-2802","article-title":"Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype","volume":"92","author":"Lowe","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025021815501462200_dgae659-B29","doi-asserted-by":"crossref","first-page":"294","DOI":"10.4158\/EP15704.OR","article-title":"Primary hyperparathyroidism, with a focus on management of the normocalcemic form: to treat or not to treat?","volume":"22","author":"Siprova","year":"2016","journal-title":"Endocr Pract"},{"key":"2025021815501462200_dgae659-B30","doi-asserted-by":"crossref","first-page":"1152464","DOI":"10.3389\/fendo.2023.1152464","article-title":"Normocalcemic primary hyperparathyroidism is an early stage of primary hyperparathyroidism according to fibroblast growth factor 23 level","volume":"14","author":"Chertok Shacham","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"2025021815501462200_dgae659-B31","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.amjmed.2004.06.037","article-title":"Characterization of normocalcemic primary hyperparathyroidism","volume":"117","author":"Tordjman","year":"2004","journal-title":"Am J Med"},{"issue":"7","key":"2025021815501462200_dgae659-B32","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1210\/jc.2013-1300","article-title":"Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations","volume":"98","author":"Cusano","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025021815501462200_dgae659-B33","doi-asserted-by":"crossref","first-page":"e1171","DOI":"10.1210\/clinem\/dgaa084","article-title":"Normocalcemic hyperparathyroidism: study of its prevalence and natural history","volume":"105","author":"Schini","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025021815501462200_dgae659-B34","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1530\/EJE-15-0595","article-title":"Serum PTH reference values established by an automated third-generation assay in vitamin D-replete subjects with normal renal function: consequences of diagnosing primary hyperparathyroidism and the classification of dialysis patients","volume":"174","author":"Souberbielle","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2025021815501462200_dgae659-B35","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1007\/s40618-023-02107-2","article-title":"Big data-based parathyroid hormone (PTH) values emphasize need for age correction","volume":"46","author":"Cavalcante","year":"2023","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2025021815501462200_dgae659-B36","first-page":"939","article-title":"Effects of estrogen on response to edetic acid infusion in postmenopausal osteoporotic women","volume":"78","author":"Cosman","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2025021815501462200_dgae659-B37","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1210\/jc.2002-021404","article-title":"Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone","volume":"88","author":"Maruani","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025021815501462200_dgae659-B38","first-page":"163","article-title":"Clinical expression of calcium sensing receptor polymorphism (A986S) in normocalcemic and asymptomatic hyperparathyroidism","volume":"48","author":"Diaz-Soto","year":"2016","journal-title":"Horm Metab Res"},{"issue":"3","key":"2025021815501462200_dgae659-B39","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/s12020-023-03476-7","article-title":"Genetic aspects underlying the normocalcemic and hypercalcemic phenotypes of primary hyperparathyroidism","volume":"82","author":"Viviani","year":"2023","journal-title":"Endocrine"},{"issue":"04","key":"2025021815501462200_dgae659-B40","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/a-0859-1020","article-title":"Normocalcemic primary hyperparathyroidism in adults without a history of nephrolithiasis or fractures: a prospective study","volume":"51","author":"Rosario","year":"2019","journal-title":"Horm Metab Res"},{"issue":"2","key":"2025021815501462200_dgae659-B41","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/cen.12819","article-title":"Normocalcaemic, vitamin D-sufficient hyperparathyroidism\u2014high prevalence and low morbidity in the general population: a long-term follow-up study, the WHO MONICA project, Gothenburg, Sweden","volume":"83","author":"Kontogeorgos","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2025021815501462200_dgae659-B42","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0039-6060(97)90357-3","article-title":"Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women","volume":"121","author":"Lundgren","year":"1997","journal-title":"Surgery"},{"issue":"6","key":"2025021815501462200_dgae659-B43","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/cen.12732","article-title":"Normocalcaemic hypoparathyroidism: prevalence and effect on bone status in older women. The OPUS study","volume":"82","author":"Palermo","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2025021815501462200_dgae659-B44","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1530\/EC-15-0030","article-title":"Normocalcemic primary hyperparathyroidism: a survey in a small village of Southern Italy","volume":"4","author":"Vignali","year":"2015","journal-title":"Endocr Connect"},{"issue":"3","key":"2025021815501462200_dgae659-B45","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s12020-012-9694-z","article-title":"Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women","volume":"42","author":"Garcia-Martin","year":"2012","journal-title":"Endocrine"},{"issue":"1):","key":"2025021815501462200_dgae659-B46","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12020-024-03768-6","article-title":"Biochemical characteristics and clinical manifestation of normocalcemic primary hyperparathyroidism","volume":"85","author":"Yankova","year":"2024","journal-title":"Endocrine"},{"issue":"6):","key":"2025021815501462200_dgae659-B47","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s40618-023-02264-4","article-title":"Twenty-four hour Holter ECG in normocalcemic and hypercalcemic patients with hyperparathyroidism","volume":"47","author":"Pepe","year":"2023","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"2025021815501462200_dgae659-B48","doi-asserted-by":"crossref","first-page":"e2609","DOI":"10.1210\/clinem\/dgaa174","article-title":"Clinical, biochemical, and radiological profile of normocalcemic primary hyperparathyroidism","volume":"105","author":"Palermo","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025021815501462200_dgae659-B49","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1055\/a-0752-4533","article-title":"Normocalcemic primary hyperparathyroidism: a comparison with the hypercalcemic form in a tertiary referral population","volume":"50","author":"Pierreux","year":"2018","journal-title":"Horm Metab Res"},{"issue":"3","key":"2025021815501462200_dgae659-B50","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00774-015-0673-3","article-title":"Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism","volume":"34","author":"Tuna","year":"2016","journal-title":"J Bone Miner Metab"},{"issue":"2","key":"2025021815501462200_dgae659-B51","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12020-012-9627-x","article-title":"Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism","volume":"42","author":"Cakir","year":"2012","journal-title":"Endocrine"},{"key":"2025021815501462200_dgae659-B52","doi-asserted-by":"crossref","first-page":"128352","DOI":"10.1155\/2012\/128352","article-title":"Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone?","volume":"2012","author":"Amaral","year":"2012","journal-title":"J Osteoporos"},{"issue":"4","key":"2025021815501462200_dgae659-B53","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00268-012-1438-y","article-title":"Surgical management of normocalcemic primary hyperparathyroidism","volume":"36","author":"Wade","year":"2012","journal-title":"World J Surg"},{"issue":"5","key":"2025021815501462200_dgae659-B54","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1590\/S0004-27302011000500003","article-title":"Normocalcemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat?","volume":"55","author":"Marques","year":"2011","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"10","key":"2025021815501462200_dgae659-B55","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1007\/s00198-022-06454-3","article-title":"Global, regional prevalence, and risk factors of osteoporosis according to the World Health Organization diagnostic criteria: a systematic review and meta-analysis","volume":"33","author":"Xiao","year":"2022","journal-title":"Osteoporos Int"},{"issue":"1","key":"2025021815501462200_dgae659-B56","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.surg.2022.05.042","article-title":"Phenotypes of primary hyperparathyroidism: does parathyroidectomy improve clinical outcomes for all?","volume":"173","author":"Armstrong","year":"2023","journal-title":"Surgery"},{"key":"2025021815501462200_dgae659-B57","doi-asserted-by":"crossref","first-page":"4558236","DOI":"10.1155\/2022\/4558236","article-title":"Occult renal calcifications in patients with normocalcemic primary hyperparathyroidism and their association with the parathyroid hormone-vitamin D axis","volume":"2022","author":"Victor","year":"2022","journal-title":"Int J Endocrinol"},{"issue":"10):","key":"2025021815501462200_dgae659-B58","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1210\/clinem\/dgae162","article-title":"Comparison of normocalcemic versus hypercalcemic primary hyperparathyroidism in a hypercalciuric renal stone population","volume":"109","author":"Halimi","year":"2024;","journal-title":"J Clin Endocrinol Metab"},{"key":"2025021815501462200_dgae659-B59","doi-asserted-by":"crossref","first-page":"107985","DOI":"10.1016\/j.diabres.2019.107985","article-title":"Increased parathyroid hormone is associated with higher fasting glucose in individuals with normocalcemic primary hyperparathyroidism and prediabetes: a pilot study","volume":"160","author":"Karras","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"2025021815501462200_dgae659-B60","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4081\/aiua.2015.1.66","article-title":"Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study","volume":"87","author":"Brardi","year":"2015","journal-title":"Arch Ital Urol Androl"},{"issue":"4","key":"2025021815501462200_dgae659-B61","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00198-014-3000-2","article-title":"Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism","volume":"26","author":"Cesareo","year":"2015","journal-title":"Osteoporos Int"},{"issue":"5","key":"2025021815501462200_dgae659-B62","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S2213-8587(20)30063-2","article-title":"Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Leere","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2025021815501462200_dgae659-B63","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.surg.2019.06.043","article-title":"Normocalcemic hyperparathyroidism: a collaborative endocrine surgery quality improvement program analysis","volume":"167","author":"Pandian","year":"2020","journal-title":"Surgery"},{"key":"2025021815501462200_dgae659-B64","doi-asserted-by":"crossref","first-page":"2150159","DOI":"10.1155\/2019\/2150159","article-title":"Do symptoms and Serum calcium levels affect the results of surgical treatment of primary hyperparathyroidism?","volume":"2019","author":"Yu","year":"2019","journal-title":"Biomed Res Int"},{"issue":"1","key":"2025021815501462200_dgae659-B65","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.surg.2016.08.054","article-title":"Differences in single gland and multigland disease are seen in low biochemical profile primary hyperparathyroidism","volume":"161","author":"Lim","year":"2017","journal-title":"Surgery"},{"issue":"2","key":"2025021815501462200_dgae659-B66","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1245\/s10434-018-6998-0","article-title":"Biochemical and skeletal outcomes of parathyroidectomy for normocalcemic (incipient) primary hyperparathyroidism","volume":"26","author":"Sho","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"2025021815501462200_dgae659-B67","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00268-022-06756-x","article-title":"Parathyroidectomy for normocalcemic primary hyperparathyroidism is associated with improved bone mineral density regardless of postoperative parathyroid hormone levels","volume":"47","author":"Lui","year":"2023","journal-title":"World J Surg"},{"issue":"3","key":"2025021815501462200_dgae659-B68","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00423-018-1659-0","article-title":"Is parathyroidectomy safe and effective in patients with normocalcemic primary hyperparathyroidism?","volume":"403","author":"Traini","year":"2018","journal-title":"Langenbecks Arch Surg"},{"issue":"3","key":"2025021815501462200_dgae659-B69","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/bjs.10739","article-title":"Effect of parathyroidectomy on quality of life and non-specific symptoms in normocalcaemic primary hyperparathyroidism","volume":"105","author":"Bannani","year":"2018","journal-title":"Br J Surg"},{"issue":"4):","key":"2025021815501462200_dgae659-B70","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/1754-9485.12728","article-title":"Better performance of four-dimension computed tomography as a localization procedure in normocalcemic primary hyperparathyroidism","volume":"62","author":"Cunha-Bezerra","year":"2018","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"6","key":"2025021815501462200_dgae659-B71","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/cen.14667","article-title":"Normocalcemic primary hyperparathyroidism: 99mTc SestaMibi SPECT\/CT results compare with hypercalcemic hyperparathyroidism","volume":"96","author":"Musumeci","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"2025021815501462200_dgae659-B72","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1210\/clinem\/dgad073","article-title":"FCH-PET\/CT in primary hyperparathyroidism with discordant\/negative MIBI scintigraphy and ultrasonography","volume":"108","author":"Koumakis","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025021815501462200_dgae659-B73","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jamcollsurg.2018.12.034","article-title":"Bilateral neck exploration for sporadic primary hyperparathyroidism: use patterns in 5,597 patients undergoing parathyroidectomy in the collaborative endocrine surgery quality improvement program","volume":"228","author":"Kiernan","year":"2019","journal-title":"J Am Coll Surg"},{"issue":"5","key":"2025021815501462200_dgae659-B74","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1177\/00031348211048844","article-title":"Effects of parathyroidectomy on normocalcemic primary hyperparathyroidism and the role of intraoperative PTH measurement","volume":"88","author":"Alameer","year":"2022","journal-title":"Am Surg"},{"issue":"2","key":"2025021815501462200_dgae659-B75","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s00268-019-05157-x","article-title":"Biochemical profile affects IOPTH kinetics and cure rate in primary hyperparathyroidism","volume":"44","author":"Graves","year":"2020","journal-title":"World J Surg"},{"issue":"4","key":"2025021815501462200_dgae659-B76","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1177\/0194599818793879","article-title":"Surgical management of normocalcemic primary hyperparathyroidism and the impact of intraoperative parathyroid hormone testing on outcome","volume":"159","author":"Trinh","year":"2018","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"11","key":"2025021815501462200_dgae659-B77","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.3390\/nu12113522","article-title":"Improving glucose homeostasis after parathyroidectomy for normocalcemic primary hyperparathyroidism with co-existing prediabetes","volume":"12","author":"Karras","year":"2020","journal-title":"Nutrients"},{"issue":"1","key":"2025021815501462200_dgae659-B78","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12872-019-1093-4","article-title":"Parathyroidectomy improves cardiovascular risk factors in normocalcemic and hypercalcemic primary hyperparathyroidism","volume":"19","author":"Beysel","year":"2019","journal-title":"BMC Cardiovasc Disord"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae659\/59640297\/dgae659.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/3\/e868\/59640297\/dgae659.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/3\/e868\/59640297\/dgae659.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:10:26Z","timestamp":1739895026000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/3\/e868\/7774817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,25]]},"references-count":78,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,9,25]]},"published-print":{"date-parts":[[2025,2,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae659","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,9,25]]}}}